NCT00554203

Sulfasalazine and Endothelial Function

Effect of Sulfasalazine on Endothelial Function

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Boston University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Experimental studies suggest that systemic inflammation leads to endothelial dysfunction and atherosclerosis. This study will examine the effects of the anti-inflammatory drug sulfasalazine on endothelial function in patients with coronary artery disease. Subjects will be treated with sulfasalazine or to placebo for six weeks. After a two-week rest period, subjects will cross over to the alternative treatment. Endothelium-dependent flow-mediated dilation of the brachial artery will be studied before and after each drug. We hypothesize that anti-inflammatory therapy will reverse endothelial dysfunction in patients with coronary artery disease.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Sulfasalazine	sulfasalazine 2 grams daily for 6 weeks

Timeline

• Start date: 2003-07-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2007-11-06
• Last updated: 2008-05-15

Locations

1 site across 1 country: United States